Clinical Trial: A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07164443) titled 'A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)' on Sept. 04.

Brief Summary: The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Met...